A Brief Cannabis Use Psychoeducation Intervention for Eating Disorder Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorSt. Joseph's Healthcare Hamilton
About this trial
The goal of this clinical trial is to learn if providing eating disorder patients with education about the consequences of cannabis (marijuana) use on mental health, gastrointestinal symptoms, eating disorder symptoms, and eating disorder treatment effectiveness increases their knowledge about the cannabis use consequences, intention to reduce cannabis use, and motivation to seek treatment for their cannabis use. The main questions this study aims to answer are:
1. Does education about consequences of cannabis use increase eating disorder patients' knowledge about the risks of cannabis use? 2. Does education about the consequences of cannabis use increase intention to reduce cannabis use and seek cannabis use treatment among those with eating disorders? 3. Does cannabis use interfere with how successful eating disorder treatment is for eating disorder patients?
All participants will receive 20 weeks of eating disorder treatment. In week 1 of treatment, participants will either be assigned to receive education about cannabis use consequences, or be assigned to a control condition where they receive education about consequences of poor sleep. Participants will be asked to complete a number of questionnaires that measure knowledge about cannabis use consequences, intention to reduce use and seek cannabis use treatment, eating disorder symptoms, and cannabis use habits. Researchers will assess how effective providing education about cannabis use consequences is on changing knowledge about cannabis use risks, intention to reduce use, and intention to seek cannabis use treatment. It will also be examined if effectiveness of eating disorder treatment is related to cannabis use habits.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A patient of St. Joseph's Healthcare Hamilton Eating Disorder Program (i.e. is currently seeking eating disorders treatment)
Participant has been diagnosed with an eating disorder
Aged 16+
Understands written and spoken English
Disqualifiers
Has not been diagnosed with an eating disorder
Under the age of 17
Does not understand written and spoken English
Trial design
Design model
Parallel
Treatments tested in this trial
Psychoeducation about risks of cannabis use
Other interventionThis intervention will provide psychoeducation to eating disorder patients about the risks of using cannabis on mood, anxiety, sleep, substance use, gastrointestinal symptoms, eating disorder symptoms, and eating disorder treatment outcomes.
Placebo control: Sleep hygiene psychoeducation
Other interventionEating disorder patients in the control condition will receive psychoeducation about impacts of poor sleep on mental health and eating disorder treatment outcomes, and strategies to improve sleep hygiene.
Treatment groups
80 Participants
are divided into 2 treatment groupsGroup A: Cannabis psychoeducation interventionExperimental treatment 1 intervention
Group B: Psychoeducation control conditionPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Knowledge of cannabis use consequences
Self-perceived knowledge about consequences of cannabis use will be measured using a 100 point visual analogue scale. Higher scores will indicate greater self-perceived knowledge about the consequences of cannabis use.
Time frame
Will be measured at baseline (i.e. 5 minutes into Session 1 of treatment for eating disorders before cannabis psychoeducation is administered), and again at 140 minutes into Session 1 of treatment for eating disorders.2
Intention to reduce cannabis use
Intention to reduce personal cannabis use will be measured using a 100 point visual analogue scale. Higher scores indicate greater intention to reduce cannabis use.
Time frame
Will be measured at baseline (i.e. 5 minutes into Session 1 of treatment for eating disorders before cannabis psychoeducation is administered), and again at 140 minutes into Session 1 of treatment for eating disorders.3
Intention to seek cannabis use treatment
Intention to seek cannabis use treatment will be measured using a 100 point visual analogue scale. Higher scores indicate greater intention to seek cannabis use treatment.
Time frame
Will be measured at baseline (i.e. 5 minutes into Session 1 of treatment for eating disorders before cannabis psychoeducation is administered), and again at 140 minutes into Session 1 of treatment for eating disorders.Secondary outcomes
1
Motivations for cannabis use
Motivations for cannabis use will be measured using the Marijuana Motives Questionnaire (5 subscales measuring motivations regarding enhancement, coping, conformity, expansion, and social). Responses range from 1 to 5, with higher scores indicating greater endorsement of that motivation. Subscale scores are calculated by taking the average score of subscale items. Motivations for cannabis use will also be measured using the Comprehensive Cannabis Motivates Questionnaire (8 subscales measuring motivations regarding food, medicinal, sleep, social, to get high, coping, conformity, creativity). Responses range from 1-5, with higher scores indicating greater endorsement of that motivation. Subscale scores are calculated by taking the average score of subscale items.
Time frame
Measured at baseline (i.e. Week 1 of CBT for eating disorders) and through treatment completion (i.e. Week 20 of CBT for eating disorders).2
Cannabis use frequency
Will be measured weekly for 20 weeks using a Likert-type question and at Week 1 and Week 20 of CBT for eating disorders using the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory.
Time frame
Weekly use will be monitored for 20 weeks using a Likert-type question. The Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory will be measured twice during Week 1 and Week 20 of CBT for eating disorders3
Eating disorder symptoms
Measured using the Eating Disorder Examination Questionnaire, which assesses for symptoms such as restrictive eating, binge eating, purging, exercise, and body image. This measure has 4 subscale scores (restraint, concern about eating, weight concerns, and shape concerns) and one global score. Items are answered on a scale of 0 to 6, with higher scores indicating greater eating disorder symptoms. Subscale scores are calculated by taking the average of subscale item scores. The global score is calculated by averaging the sum of the 4 subscale scores.
Time frame
Administered at Week 1 (baseline) and Week 20 of CBT for eating disorders.4
Impairment caused by eating disorder
Measured using the Clinical Impairment Assessment. Assesses for impairment caused by eating disorder symptoms, such as negative emotions, concentration difficulties, social impairment. Items are responded to on a scale of 0 to 3, with higher scores indicating greater impairment on that item. A total score is calculated by summing all item scores.
Time frame
Administered at Week 1 and Week 20 of CBT for eating disorders.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: